Chai Discovery Raises USD 70m to Advance Antibody Platform

AI biotech startup Chai Discovery has secured USD 70 million in Series A funding led by Menlo Ventures, with participation from OpenAI, Thrive Capital and DST Global Partners. The company's Chai-2 platform achieves 20% success rate in de novo antibody design — 200 times higher than traditional computational methods — by generating binders from target antigen inputs alone. Founder Matthew McPartlon likened the breakthrough to "having a master locksmith craft keys instead of searching through millions".

Chai Discovery will use the funds to expand its AI platform for previously undruggable targets. The company previously released open-source foundation model Chai-1 for molecular structure prediction and has accelerated antibody discovery timelines from 3 years to 2 weeks. Investors include veterans from OpenAI, Meta FAIR and Google X.

According to PharmCube's NextBiopharm® database, antibody-based therapies are the most researched modalities among currently active programs. Click here to request a free trial for NextBiopharm®.

Daily News
BMS Secures First Global Approval for a CELMoD with MM Nod from US
2026-08-17
Pfizer Initiates Phase III for First-in-Class IL-4×IL-13×TSLP Trispecific
2026-08-17
3SBio Licences Hybio's Semaglutide Injection in China
2026-08-14
Allist In-Licenses ArriVent's First-in-Class MUC16×NaPi2b Bispecific ADC
2026-08-14
MagicRNA Closes Series B to Advance In Vivo CAR-T
2026-08-14
Latest Report
2026 TOP-25 Drug Targets
Details